3.2 Heart Failure and Cardiac Disease Progression

Cardiac decline on a 150-item RN board

Heart failure is one of the most common non-cancer hospice diagnoses, and it is a favorite CHPN trap because the patient can look “stable” between crises. Domain 1.C wants the pattern: New York Heart Association (NYHA) class III–IV limitation, stacked hospitalizations, shrinking response to diuretics, and a device or infusion that now collides with dying. The CHPN RN coordinates; you do not implant defibrillators, left ventricular assist devices, or inotrope catheters.

HFrEF versus HFpEF, and why NYHA still matters

Heart failure with reduced ejection fraction (HFrEF) is a left-ventricular ejection fraction of 40% or less—a squeezing problem. Heart failure with preserved ejection fraction (HFpEF) is typically 50% or greater—a filling problem, more often in older adults with hypertension, diabetes, obesity, and atrial fibrillation. Exam writers love the false rule that only a low ejection fraction qualifies for hospice. A patient with HFpEF, anasarca, and dyspnea at rest can be as hospice-eligible as a patient with an ejection fraction of 15%.

NYHA class III means marked limitation: ordinary activity (dressing, walking across a room) causes symptoms, but the patient is comfortable at rest. NYHA class IV means symptoms at rest. Hospice conversations cluster in III–IV, especially when guideline-directed therapy is already maximized or no longer tolerated. Do not wait for a single magic ejection-fraction cutoff. Recurrent hospitalizations—two or more unplanned stays in six months for congestion, arrhythmia, or kidney injury—are often the decline signal families recognize before they accept the word hospice.

Inotropes, hospice election, and home infusions

Intravenous dobutamine or milrinone can reduce rest dyspnea and congestion when the pump can no longer respond to oral therapy. That is palliation, not a cure. It is also disease-modifying support: many hospice programs cannot pay for continuous home inotropes under the Medicare hospice benefit, some partner with an advanced-heart-failure clinic in an “open-access” model, and some will continue a time-limited infusion while the goal is comfort at home. There is no single national switch that says every inotrope must stop the morning hospice is elected. The CHPN RN names the implication: electing hospice may mean the infusion vendor, the pump, and the laboratory monitoring are no longer funded the same way. Coordinate with the hospice medical director and the heart-failure team before the family is surprised by a stopped drip.

Home milrinone or dobutamine exists in selected programs with infusion nursing, implantable or midline access, and a plan for hypotension, arrhythmia, and line infection. The CHPN RN does not independently start the drug, place the line as a certified implanter, or promise that every hospice will honor the drip.

ICD shocks, pacemakers, and LVAD complexity

An implantable cardioverter-defibrillator (ICD) can deliver painful shocks while a patient is actively dying from pump failure or respiratory collapse. Those shocks do not restore a meaningful life; they terrorize the room. Deactivating tachyarrhythmia therapies after an informed conversation with the patient or legal decision-maker is not euthanasia. The device simply stops shocking. Bradycardia pacing, if present in a dual-function device, is a separate decision; many teams leave pacing on because abrupt pacemaker-dependent collapse can increase dyspnea. A magnet may temporarily inhibit shocks in a crisis; lasting deactivation is a reprogramming visit by electrophysiology or another privileged clinician. The CHPN RN raises the topic early, documents the goal, and coordinates the visit. You do not reprogram the generator yourself.

A left ventricular assist device (LVAD) as destination therapy (not as a bridge to transplant) creates a hospice problem set: driveline infection, anticoagulation, battery and controller teaching, and the meaning of turning the pump off. Deactivating an LVAD usually leads to death within minutes to hours from loss of forward flow. That conversation belongs with the VAD team, the hospice medical director, and the family—never as a surprise bedside experiment. Bridge-to-transplant patients who elect hospice have usually already left the transplant pathway; still, coordinate rather than assume. The CHPN RN does not implant, explant, or “turn off” a pump without that team structure.

Diuretic resistance, hyponatremia, cardiorenal decline, angina versus dying

Diuretic resistance is congestion that no longer yields to escalating loop diuretics, even with thiazide add-on, inotropes, or sequential blockade. Hyponatremia in advancing heart failure is a prognostic warning, not just a sodium number to chase with hypertonic saline on hospice. Cardiorenal syndrome is the loop in which worse congestion injures the kidney and worse kidney function blocks diuresis. Creatinine creep plus oliguria plus rest dyspnea is a trajectory, not a one-time lab error.

Angina is ischemic chest pain; treat it as pain (nitrates, opioids, oxygen if hypoxemic, rest). Dying from heart failure is often air hunger, Cheyne–Stokes breathing, cool mottled skin, and fading pulse—not a textbook pressure-like angina. The CHPN RN still treats chest pain if it is present, and still treats dyspnea if that is the dominant distress. Do not withhold opioids for air hunger because “this is a heart patient.” Opioid titration for dyspnea is taught later; the assessment point here is to name the symptom correctly so the plan matches the dying physiology rather than an old catheterization report.